{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:40:18Z","timestamp":1790912418705,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304102"],"award-info":[{"award-number":["2022YFC2304102"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the National Key Research and Development Program of China","award":["2022YFC2303300"],"award-info":[{"award-number":["2022YFC2303300"]}]},{"name":"the Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDB0490000"],"award-info":[{"award-number":["XDB0490000"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272301"],"award-info":[{"award-number":["82272301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Anhui Provincial Key Research and Development Project","award":["2022i01020025"],"award-info":[{"award-number":["2022i01020025"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["WK9100000001"],"award-info":[{"award-number":["WK9100000001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03888-y","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:55:16Z","timestamp":1735898116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["FcRn-guided antigen trafficking enhances cancer vaccine efficacy"],"prefix":"10.1007","volume":"74","author":[{"given":"Mengyu","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muziying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyi","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songquan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoubing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengchuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"5","key":"3888_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007015","volume":"15","author":"P Bentkowski","year":"2019","unstructured":"Bentkowski P, Radwan J (2019) Evolution of major histocompatibility complex gene copy number. PLoS Comput Biol 15(5):e1007015","journal-title":"PLoS Comput Biol"},{"issue":"12","key":"3888_CR2","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","volume":"22","author":"N Pishesha","year":"2022","unstructured":"Pishesha N, Harmand TJ, Ploegh HL (2022) A guide to antigen processing and presentation. Nat Rev Immunol 22(12):751\u2013764","journal-title":"Nat Rev Immunol"},{"key":"3888_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","volume":"21","author":"D Dersh","year":"2021","unstructured":"Dersh D, Holl\u00fd J, Yewdell JW (2021) A few good peptides: MHC class I- based cancer immunosurveillance and immunoevasion. Nat Rev Immunol 21:116\u2013128","journal-title":"Nat Rev Immunol"},{"key":"3888_CR4","first-page":"15","volume-title":"MHC\/HLA class I\u00a0loss in\u00a0cancer cells","author":"F Garrido","year":"2019","unstructured":"Garrido F (2019) MHC\/HLA class I\u00a0loss in\u00a0cancer cells. Springer, Cham, pp 15\u201378"},{"issue":"9","key":"3888_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nmeth.4380","volume":"14","author":"M Stoeckius","year":"2017","unstructured":"Stoeckius M et al (2017) Simultaneous epitope and transcriptome measurement in single cells. Nat Methods 14(9):865\u2013868","journal-title":"Nat Methods"},{"issue":"7549","key":"3888_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter S et al (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520(7549):692\u2013696","journal-title":"Nature"},{"key":"3888_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fimmu.2017.00278","volume":"8","author":"W Fleri","year":"2017","unstructured":"Fleri W et al (2017) The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. Front Immunol 8:278","journal-title":"Front Immunol"},{"issue":"1","key":"3888_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13099-022-00495-z","volume":"14","author":"J Dey","year":"2022","unstructured":"Dey J et al (2022) Designing a novel multi-epitope vaccine to evoke a robust immune response against pathogenic multidrug-resistant Enterococcus faecium bacterium. Gut Pathogens 14(1):21","journal-title":"Gut Pathogens"},{"key":"3888_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.abq3773","volume":"377","author":"C Dacon","year":"2022","unstructured":"Dacon C, Tucker C, Peng L, Lee CCD, Lin TH, Yuan M, Cong Y, Wang L, Purser L, Williams JK, Pyo CW (2022) Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 377:728\u2013735","journal-title":"Science"},{"issue":"7","key":"3888_CR10","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.chom.2021.05.010","volume":"29","author":"A Grifoni","year":"2021","unstructured":"Grifoni A, Sidney J, Vita R, Peters B, Crotty S, Weiskopf D, Sette A (2021) SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe 29(7):1076\u20131092","journal-title":"Cell Host Microbe"},{"issue":"2","key":"3888_CR11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1039\/C5SC03892H","volume":"7","author":"M Skwarczynski","year":"2016","unstructured":"Skwarczynski M, Toth I (2016) Peptide-based synthetic vaccines. Chem Sci 7(2):842\u2013854","journal-title":"Chem Sci"},{"issue":"7738","key":"3888_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB et al (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738):234\u2013239","journal-title":"Nature"},{"issue":"3","key":"3888_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1074-7613(03)00051-7","volume":"18","author":"MF Princiotta","year":"2003","unstructured":"Princiotta MF et al (2003) Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18(3):343\u2013354","journal-title":"Immunity"},{"issue":"12","key":"3888_CR14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nri1250","volume":"3","author":"JW Yewdell","year":"2003","unstructured":"Yewdell JW, Reits E, Neefjes J (2003) Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol 3(12):952\u2013961","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"3888_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/intimm\/4.10.1113","volume":"4","author":"V Calin-Laurens","year":"1992","unstructured":"Calin-Laurens V et al (1992) High efficiency of endogenous antigen presentation by MHC class II molecules. Int Immunol 4(10):1113\u20131121","journal-title":"Int Immunol"},{"issue":"10","key":"3888_CR16","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.4049\/jimmunol.172.10.6129","volume":"172","author":"T Storni","year":"2004","unstructured":"Storni T, Bachmann MF (2004) Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J Immunol 172(10):6129\u20136135","journal-title":"J Immunol"},{"issue":"1","key":"3888_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4049\/jimmunol.180.1.309","volume":"180","author":"S Kreiter","year":"2008","unstructured":"Kreiter S et al (2008) Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol 180(1):309\u2013318","journal-title":"J Immunol"},{"issue":"7780","key":"3888_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach E et al (2019) MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574(7780):696\u2013701","journal-title":"Nature"},{"issue":"8","key":"3888_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1080\/15548627.2020.1769973","volume":"16","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K et al (2020) Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer. Autophagy 16(8):1524\u20131525","journal-title":"Autophagy"},{"issue":"14","key":"3888_CR20","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.7150\/jca.38330","volume":"11","author":"JQ Hu","year":"2020","unstructured":"Hu JQ et al (2020) IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto\u2019s thyroiditis overcomes immune escape in vitro. J Cancer 11(14):4250\u20134260","journal-title":"J Cancer"},{"issue":"2","key":"3888_CR21","doi-asserted-by":"publisher","first-page":"e000692","DOI":"10.1136\/jitc-2020-000692","volume":"8","author":"K Stifter","year":"2020","unstructured":"Stifter K et al (2020) IFN-\u03b3 treatment protocol for MHC-Ilo\/PD-L1+ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential. J Immunother Cancer 8(2):e000692","journal-title":"J Immunother Cancer"},{"issue":"32","key":"3888_CR22","doi-asserted-by":"publisher","first-page":"13312","DOI":"10.1074\/jbc.M117.794248","volume":"292","author":"EGW Schmidt","year":"2017","unstructured":"Schmidt EGW et al (2017) Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin. J Biol Chem 292(32):13312\u201313322","journal-title":"J Biol Chem"},{"issue":"4","key":"3888_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1097-2765(01)00230-1","volume":"7","author":"WL Martin","year":"2001","unstructured":"Martin WL et al (2001) Crystal structure at 2.8 A of an FcRn\/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 7(4):867\u2013877","journal-title":"Mol Cell"},{"issue":"5","key":"3888_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1600-0854.2009.00887.x","volume":"10","author":"Z Gan","year":"2009","unstructured":"Gan Z et al (2009) Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 10(5):600\u2013614","journal-title":"Traffic"},{"issue":"4","key":"3888_CR25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.4049\/jimmunol.1700924","volume":"200","author":"Y Ma","year":"2018","unstructured":"Ma Y et al (2018) Truncation of the murine neonatal fc receptor cytoplasmic tail does not alter IgG metabolism or transport in vivo. J Immunol 200(4):1413\u20131424","journal-title":"J Immunol"},{"issue":"2","key":"3888_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.sbi.2010.01.010","volume":"20","author":"DB Tesar","year":"2010","unstructured":"Tesar DB, Bj\u00f6rkman PJ (2010) An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G. Curr Opin Struct Biol 20(2):226\u2013233","journal-title":"Curr Opin Struct Biol"},{"issue":"5","key":"3888_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ejcb.2017.06.005","volume":"96","author":"IS Mahmoud","year":"2017","unstructured":"Mahmoud IS et al (2017) Signal dependent transport of a membrane cargo from early endosomes to recycling endosomes. Eur J Cell Biol 96(5):418\u2013431","journal-title":"Eur J Cell Biol"},{"issue":"11","key":"3888_CR28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri3298","volume":"12","author":"J Girard","year":"2012","unstructured":"Girard J, Moussion C, F\u00f6rster R (2012) HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 12(11):762\u2013773","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3888_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L (2021) mRNA vaccine for cancer immunotherapy. Mol Cancer 20(1):41","journal-title":"Mol Cancer"},{"issue":"51","key":"3888_CR30","doi-asserted-by":"publisher","first-page":"2303261","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong Y et al (2023) Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater 35(51):2303261","journal-title":"Adv Mater"},{"key":"3888_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L et al (2021) mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm 601:120586","journal-title":"Int J Pharm"},{"issue":"1","key":"3888_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1535-7163.MCT-14-0584","volume":"14","author":"TJ Lahusen","year":"2015","unstructured":"Lahusen TJ, Deng C (2015) SRT1720 induces lysosomal-dependent cell death of breast cancer cells. Mol Cancer Ther 14(1):183\u2013192","journal-title":"Mol Cancer Ther"},{"issue":"36","key":"3888_CR33","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1016\/j.vaccine.2009.05.009","volume":"27","author":"W Zhou","year":"2009","unstructured":"Zhou W et al (2009) Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB\/c mice model. Vaccine 27(36):5013\u20135019","journal-title":"Vaccine"},{"issue":"1","key":"3888_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-5-20","volume":"5","author":"M Mansour","year":"2007","unstructured":"Mansour M et al (2007) Therapy of established B16\u2013F10 melanoma tumors by a single vaccination of CTL\/T helper peptides in VacciMax\u00ae. J Transl Med 5(1):1\u20138","journal-title":"J Transl Med"},{"issue":"1","key":"3888_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0523-2","volume":"7","author":"M F\u00e4ssler","year":"2019","unstructured":"F\u00e4ssler M et al (2019) Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J ImmunoTherapy Cancer 7(1):1\u201312","journal-title":"J ImmunoTherapy Cancer"},{"issue":"10","key":"3888_CR36","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1158\/2326-6066.CIR-20-0270","volume":"8","author":"KE Kortekaas","year":"2020","unstructured":"Kortekaas KE et al (2020) CD39 identifies the CD4+ tumor-specific T-cell population in human cancer. Cancer Immunol Res 8(10):1311\u20131321","journal-title":"Cancer Immunol Res"},{"key":"3888_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107122","volume":"202","author":"Y Shen","year":"2024","unstructured":"Shen Y et al (2024) CD39hi identifies an exhausted tumor-reactive CD8+ T cell population associated with tumor progression in human gastric cancer. Pharmacol Res 202:107122","journal-title":"Pharmacol Res"},{"key":"3888_CR38","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2147\/OTT.S297272","volume":"14","author":"W Zhu","year":"2021","unstructured":"Zhu W et al (2021) CD8+CD39+ T cells mediate anti-tumor cytotoxicity in bladder cancer. Onco Targets Ther 14:2149\u20132161","journal-title":"Onco Targets Ther"},{"issue":"10","key":"3888_CR39","first-page":"1421","volume":"21","author":"A Rosas-Taraco","year":"2010","unstructured":"Rosas-Taraco A et al (2010) Targeting and retention of antigen to the endoplasmic reticulum enhances immune tumor protection. Hum Gene Ther 21(10):1421\u20131421","journal-title":"Hum Gene Ther"},{"issue":"10","key":"3888_CR40","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/1061186X.2021.1919124","volume":"29","author":"DH Mart\u00ednez-Puente","year":"2021","unstructured":"Mart\u00ednez-Puente DH et al (2021) Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect. J Drug Target 29(10):1102\u20131110","journal-title":"J Drug Target"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03888-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03888-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03888-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T01:09:53Z","timestamp":1739149793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03888-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3888"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03888-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare that they have no conflict of interest relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"54"}}